Piedmont Investment Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-15,803
| Closed | -$307K | – | 2927 |
|
|
2018
Q1 | $307K | Buy |
15,803
+569
| +4% | +$11.2K | 0.01% | 563 |
|
|
2017
Q4 | $254K | Sell |
15,234
-954
| -6% | -$17.5K | 0.01% | 628 |
|
|
2017
Q3 | $329K | Buy |
16,188
+253
| +2% | +$4.84K | 0.01% | 541 |
|
|
2017
Q2 | $257K | Buy |
+15,935
| New | +$235K | 0.01% | 615 |
|
|
2017
Q1 | – | Sell |
-26
| Closed | -$344 | – | 690 |
|
|
2016
Q4 | $344 | Sell |
26
-16
| -38% | -$274 | ﹤0.01% | 672 |
|
|
2016
Q3 | $995 | Hold |
42
| – | – | ﹤0.01% | 437 |
|
|
2016
Q2 | $1.21K | Hold |
42
| – | – | ﹤0.01% | 362 |
|
|
2016
Q1 | $1.34K | Hold |
42
| – | – | ﹤0.01% | 358 |
|
|
2015
Q4 | $1.79K | Buy |
+42
| New | +$1.68K | ﹤0.01% | 344 |
|
|
2014
Q2 | – | Sell |
-153
| Closed | -$4.04K | – | 349 |
|
|
2014
Q1 | $4.04K | Hold |
153
| – | – | ﹤0.01% | 229 |
|
|
2013
Q4 | $3.85K | Sell |
153
-35
| -19% | -$781 | ﹤0.01% | 222 |
|
|
2013
Q3 | $3.85K | Sell |
188
-13
| -6% | -$268 | ﹤0.01% | 208 |
|
|
2013
Q2 | $4.01K | Buy |
+201
| New | +$3.57K | ﹤0.01% | 255 |
|
Piedmont Investment Advisors's IPXL Position: Q2 2018 in Review
Piedmont Investment Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 15,803 shares — an estimated $307K sold.
Piedmont Investment Advisors first reported a position in IPXL in Q2 2013 and held it in 13 quarters. The position peaked at $329K in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Piedmont Investment Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Piedmont Investment Advisors sold 15,803 Impax Laboratories, Inc. shares in Q2 2018, an estimated $307K.
- Piedmont Investment Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 13 quarters.
- Piedmont Investment Advisors's Impax Laboratories, Inc. position peaked at $329K in Q3 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Piedmont Investment Advisors's 13F filing for Q2 2018, filed 27 Jul 2018.